These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 20164787)

  • 21. Sinus rhythm restoration affects collagen turnover in patients with persistent atrial fibrillation.
    Kallergis EM; Goudis CA; Kanoupakis EM; Mavrakis HE; Maliaraki NE; Tzanakis N; Vardas PE
    Europace; 2014 Dec; 16(12):1726-30. PubMed ID: 25142742
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Drug-induced changes in fibrillation cycle length and organization index can predict chemical cardioversion of long-lasting atrial fibrillation with bepridil alone or in combination with aprindine.
    Fujiki A; Sakabe M; Nishida K; Sugao M; Tsuneda T; Iwamoto J; Mizumaki K; Inoue H
    Circ J; 2004 Dec; 68(12):1139-45. PubMed ID: 15564697
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Angiotensin II blockade, YKL-40 and maintenance of sinus rhythm after electrical cardioversion for atrial fibrillation.
    Tveit A; Seljeflot I; Smith P; Arnesen H; Svendsen JH
    Immunobiology; 2013 Oct; 218(10):1256-60. PubMed ID: 23731775
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Use of bepridil in combination with Ic antiarrhythmic agent in converting persistent atrial fibrillation to sinus rhythm.
    Imai S; Saito F; Takase H; Enomoto M; Aoyama H; Yamaji S; Yokoyama K; Yagi H; Kushiro T; Hirayama A
    Circ J; 2008 May; 72(5):709-15. PubMed ID: 18441448
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Impact of postprocedural antiarrhythmic drug therapy with bepridil on maintaining sinus rhythm after catheter ablation for persistent atrial fibrillation.
    Kondo T; Miake J; Kato M; Ogura K; Iitsuka K; Yamamoto K
    J Cardiol; 2016 Sep; 68(3):229-35. PubMed ID: 26654806
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Randomized trial of angiotensin II-receptor blocker vs. dihydropiridine calcium channel blocker in the treatment of paroxysmal atrial fibrillation with hypertension (J-RHYTHM II study).
    Yamashita T; Inoue H; Okumura K; Kodama I; Aizawa Y; Atarashi H; Ohe T; Ohtsu H; Kato T; Kamakura S; Kumagai K; Kurachi Y; Koretsune Y; Saikawa T; Sakurai M; Sato T; Sugi K; Nakaya H; Hirai M; Hirayama A; Fukatani M; Mitamura H; Yamazaki T; Watanabe E; Ogawa S;
    Europace; 2011 Apr; 13(4):473-9. PubMed ID: 21148662
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Usefulness and safety of bepridil in converting persistent atrial fibrillation to sinus rhythm.
    Fujiki A; Tsuneda T; Sugao M; Mizumaki K; Inoue H
    Am J Cardiol; 2003 Aug; 92(4):472-5. PubMed ID: 12914884
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The role of infection in the development of non-valvular atrial fibrillation: up-regulation of Toll-like receptor 2 expression levels on monocytes.
    Ichiki H; Orihara K; Hamasaki S; Ishida S; Oketani N; Iriki Y; Ninomiya Y; Okui H; Kuwahata S; Fujita S; Matsushita T; Yoshifuku S; Oba R; Hirai H; Nagata K; Tei C
    J Cardiol; 2009 Feb; 53(1):127-35. PubMed ID: 19167648
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Rhythm control versus rate control in patients with persistent atrial fibrillation. Results of the HOT CAFE Polish Study.
    Opolski G; Torbicki A; Kosior D; Szulc M; Zawadzka M; Pierścińska M; Kołodziej P; Stopiński M; Wozakowska-Kapłon B; Achremczyk P; Rabczenko D
    Kardiol Pol; 2003 Jul; 59(7):1-16; discussion 15-16. PubMed ID: 14560344
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Atrial fibrillation and risk of clinical events in chronic heart failure with and without left ventricular systolic dysfunction: results from the Candesartan in Heart failure-Assessment of Reduction in Mortality and morbidity (CHARM) program.
    Olsson LG; Swedberg K; Ducharme A; Granger CB; Michelson EL; McMurray JJ; Puu M; Yusuf S; Pfeffer MA;
    J Am Coll Cardiol; 2006 May; 47(10):1997-2004. PubMed ID: 16697316
    [TBL] [Abstract][Full Text] [Related]  

  • 31. N-3 polyunsaturated fatty acids administration does not reduce the recurrence rates of atrial fibrillation and inflammation after electrical cardioversion: a prospective randomized study.
    Ozaydın M; Erdoğan D; Tayyar S; Uysal BA; Doğan A; Içli A; Ozkan E; Varol E; Türker Y; Arslan A
    Anadolu Kardiyol Derg; 2011 Jun; 11(4):305-9. PubMed ID: 21543294
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Circulating levels of collagen type I degradation marker depend on the type of atrial fibrillation.
    Tziakas DN; Chalikias GK; Papanas N; Stakos DA; Chatzikyriakou SV; Maltezos E
    Europace; 2007 Aug; 9(8):589-96. PubMed ID: 17485436
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Direct comparison of mid-regional pro-atrial natriuretic peptide with N-terminal pro B-type natriuretic peptide in the diagnosis of patients with atrial fibrillation and dyspnoea.
    Eckstein J; Potocki M; Murray K; Breidthardt T; Ziller R; Mosimann T; Klima T; Hoeller R; Moehring B; Sou SM; Rubini Gimenez M; Morgenthaler NG; Mueller C
    Heart; 2012 Oct; 98(20):1518-22. PubMed ID: 22865868
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pharmacological conversion of atrial fibrillation in the patients of Graves' disease.
    Kunii Y; Uruno T; Matsumoto M; Mukasa K; Noh J; Ito K; Akaishi M; Hori S; Nakazawa H
    Tokai J Exp Clin Med; 2012 Dec; 37(4):107-12. PubMed ID: 23238902
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Natriuretic peptides in patients with atrial fibrillation and advanced chronic heart failure: determinants and prognostic value of (NT-)ANP and (NT-pro)BNP.
    Rienstra M; Van Gelder IC; Van den Berg MP; Boomsma F; Van Veldhuisen DJ
    Europace; 2006 Jul; 8(7):482-7. PubMed ID: 16798760
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Natriuretic peptide levels predict recurrence of atrial fibrillation after radiofrequency catheter ablation.
    den Uijl DW; Delgado V; Tops LF; Ng AC; Boersma E; Trines SA; Zeppenfeld K; Schalij MJ; van der Laarse A; Bax JJ
    Am Heart J; 2011 Jan; 161(1):197-203. PubMed ID: 21167354
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The effect of sinus rhythm restoration on high-sensitivity C-reactive protein levels and their association with long-term atrial fibrillation recurrence after electrical cardioversion.
    Celebi OO; Celebi S; Canbay A; Ergun G; Aydogdu S; Diker E
    Cardiology; 2011; 118(3):168-74. PubMed ID: 21654170
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Prospective randomized study comparing amiodarone vs. amiodarone plus losartan vs. amiodarone plus perindopril for the prevention of atrial fibrillation recurrence in patients with lone paroxysmal atrial fibrillation.
    Yin Y; Dalal D; Liu Z; Wu J; Liu D; Lan X; Dai Y; Su L; Ling Z; She Q; Luo K; Woo K; Dong J
    Eur Heart J; 2006 Aug; 27(15):1841-6. PubMed ID: 16825288
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Efficacy and tolerability of oral propafenone versus quinidine in the treatment of recent onset atrial fibrillation: A randomized, prospective study.
    Kosior DA; Kochanowski J; Scisło P; Piatkowski R; Postuła M; Rabczenko D; Opolski G
    Cardiol J; 2009; 16(6):521-7. PubMed ID: 19950088
    [TBL] [Abstract][Full Text] [Related]  

  • 40. C-reactive protein but not atrial dysfunction predicts recurrences of atrial fibrillation after cardioversion in patients with preserved left ventricular function.
    Lombardi F; Tundo F; Belletti S; Mantero A; Melzi D'eril GV
    J Cardiovasc Med (Hagerstown); 2008 Jun; 9(6):581-8. PubMed ID: 18475126
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.